A development in the treatment of Alzheimer’s disease moved a biotech stock sharply higher Tuesday. Here’s some small stocks making big moves on Tuesday, March 6, 2018 (as of 4 pm EST):
ProMIS Neurosciences, Inc. (TSX:PMN), a biotech stock, jumped 43% to $0.52 on Tuesday after announcing that its lead product candidate for Alzheimer’s disease, PMN310, showed similar ability to cross the blood brain barrier and penetrate the central nervous system compared to aducanumab.
As well, shares of Clearwater Seafoods Incorporated (TSX:CLR) slipped 9% to $4.25 as the vertically-integrated seafood company released its 2017 financial results, adding that its gross margin declined to 17.7% as a percentage of sales, from 23.6% in 2016, as overall sales volumes were offset by the reduction of higher-margin shrimp volumes and an overall product mix and size shift towards lower-margin products.
Maple Leaf Green World Inc. (TSXV:MGW), meanwhile, reported that its proposed cannabis cultivation facility located in Telkwa, British Columbia, is expected to be completed in the middle of March as scheduled. Maple Leaf Green stock moved up 17% to $1.03 following the announcement.
Finally, ProSmart Enterprises Inc. (TSXV:PROS) shares gained as much as 21% before ending unchanged at $0.66 after the global online sports network announced that it has agreed to acquire DL Hockey Consulting (Shenzhen) Limited and DL Hockey Consulting Limited, which operates a hockey club and skills camps in China, where 650 skating rinks are being built as part of its winter sports development plan in the run up to their hosting of the 2022 Winter Olympics.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
ProMIS Neurosciences, Inc. (TSX:PMN), a biotech stock, jumped 43% to $0.52 on Tuesday after announcing that its lead product candidate for Alzheimer’s disease, PMN310, showed similar ability to cross the blood brain barrier and penetrate the central nervous system compared to aducanumab.
